Agios

Commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases. Read more:

[Agios @AgiosPharma]

#AgiosNews: We have obtained exclusive global rights to a novel, next‑generation, oral spleen tyrosine kinase (SYK) inhibitor from Oscotec, and will advance this for immune thrombocytopenia (ITP), a rare autoimmune blood disorder.

Read more: https://t.co/k3tQkYvOvy

[Agios @AgiosPharma]

#AgiosNews: We will not advance our next-generation oral pyruvate kinase (PK) activator in lower-risk myelodysplastic syndromes (LR-MDS), following Phase 2b results that did not meet our predefined threshold to support further development.

Read more: https://t.co/Bcoiar9h7g

[Agios @AgiosPharma]

#AgiosNews: @EU_Commission granted authorization for our first-in-class oral pyruvate kinase (PK) activator in adults for the treatment of anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia. Read more: https://t.co/spJH99YkUo

[Agios @AgiosPharma]

#AgiosNews: We submitted an sNDA to the @US_FDA for U.S. accelerated approval of our first-in-class pyruvate kinase (PK) activator in #SickleCellDisease. We expect acceptance notice in the third quarter of 2026, following FDA’s 60-day review period. Read more: https://t.co/xa61k7jGbG

[Agios @AgiosPharma]

At #EHA2026, we’re excited to showcase new data highlighting our first-in-class pyruvate kinase (PK) activator – including a plenary session with RISE UP Phase 3 #SickleCellDisease trial results – and connect with the #hematology community. Read more: https://t.co/SXsI72Rh4I

[Agios @AgiosPharma]

Members of our Leadership Team will participate in fireside chats at the Bank of America (May 12) and RBC Capital Markets (May 19) 2026 healthcare conferences.

Live webcasts and replays will be on the Investors section of our website.

Listen and learn more: https://t.co/WhCHVQTCNe

[Agios @AgiosPharma]

Great conversations at the 2026 @amcporg Annual Meeting. Our team’s #HEOR research on #SickleCellDisease confirms that progress demands system-wide approaches to address the real barriers patients face.

#AMCP #RareDisease

[Agios @AgiosPharma]

We're at the 2026 @ASPHO_hq Conference, ready to explore scientific advances in pediatric #hematology and connect with #raredisease communities. Find us at booth #307 to learn about the latest progress from our pyruvate kinase activation portfolio.

#ASPHO2026

[Agios @AgiosPharma]

#AgiosNews: Today we reported our first quarter 2026 financial results, along with recent business highlights. Read the press release and tune into the webcast this morning at 8:00 a.m. ET: https://t.co/yMQqVLc6ZX

[Agios @AgiosPharma]

Our 2026 Environmental, Social, and Governance (ESG) report is now available. It highlights our partnerships with rare disease communities to advance science and access to new medicines, and our commitment to a safe, inclusive, and purpose-driven workplace: https://t.co/M0VaKbomGo

[Agios @AgiosPharma]

We are hosting a conference call and live webcast on Wednesday, April 29, at 8:00 a.m. ET to report and discuss our first quarter 2026 financial results and other business highlights. Instructions on how to join the webcast are available here: https://t.co/n6YPgP90kJ

[Agios @AgiosPharma]

#AgiosNews: We will pursue U.S. accelerated approval for our first-in-class oral pyruvate kinase (PK) activator in #SickleCellDisease, following completion of our pre-supplemental New Drug Application (sNDA) meeting with the @US_FDA. Read more: https://t.co/FLbZVm0ewd

[Agios @AgiosPharma]

#AgiosNews: @EDE_UAE approved our first-in-class oral pyruvate kinase (PK) activator for adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia – the only medicine approved in the UAE for this population. Read more: https://t.co/XyVWvHV3GP

[Agios @AgiosPharma]

Members of our Leadership Team will join a fireside chat at the TD Cowen Health Care Conference on March 2.

The live webcast will be on the Investors section of our website, with a replay archived for at least 2 weeks. Listen and learn more: https://t.co/2xs7FdLbsg

[Agios @AgiosPharma]

#AgiosNews: Today we reported our fourth quarter and full year 2025 financial results, along with recent business highlights. Read the press release and tune into the webcast this morning at 8:00 a.m. ET: https://t.co/Ij5zRm0fbh

[Agios @AgiosPharma]

We are hosting a conference call and live webcast on Thursday, February 12, at 8:00 a.m. ET to report and discuss our fourth quarter and full year 2025 financial results and other business highlights. Instructions on how to join the webcast are available here: https://t.co/tsd7tvVEmX

[Agios @AgiosPharma]

We’re on-site for #JPM26. Ahead of the meeting, we outlined our 2026 strategic priorities and key milestones across our #raredisease portfolio. Read our press release and tune in to our presentation on Wednesday, 1/14, at 8:15 a.m. PT to learn more: https://t.co/nnH9wM5OmJ

[Agios @AgiosPharma]

At #JPM26, we will share updates on our 2026 strategic priorities, our #raredisease pipeline, and the future outlook for the company.

Learn more by tuning into our company presentation on Wednesday, January 14 at 8:15 a.m. PT / 11:15 a.m. ET: https://t.co/sct3RokmXP

[Agios @AgiosPharma]

#AgiosNews: @US_FDA approved our first-in-class pyruvate kinase (PK) activator for the treatment of anemia in adults with alpha- or beta-thalassemia – regardless of transfusion status.

Read more here: https://t.co/sP9t49O2dX

[Agios @AgiosPharma]

#AgiosNews: Today we announced that the @US_FDA has not yet issued a decision on the sNDA for our first-in-class pyruvate kinase activator in adults with thalassemia and that the sNDA remains under active review.

Read more here: https://t.co/0QDKRoWLVr